Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Current Gastroenterology Reports
Erschienen in: Current Gastroenterology Reports 6/2011

01.12.2011 | Stomach and Duodenum (Joseph R. Pisegna, Section Editor)

Gastric Infection by Helicobacter pylori

verfasst von: George Sachs, David R. Scott, Yi Wen

Erschienen in: Current Gastroenterology Reports | Ausgabe 6/2011

Einloggen, um Zugang zu erhalten

Abstract

Helicobacter pylori infects half of the world’s population and plays a causal role in ulcer disease and gastric cancer. This pathogenic neutralophile uniquely colonizes the acidic gastric milieu through the process of acid acclimation. Acid acclimation is the ability of the organism to maintain periplasmic pH near neutrality in an acidic environment to prevent a fall in cytoplasmic pH in order to maintain viability and growth in acid. Recently, due to an increase in antibiotic resistance, the rate of H. pylori eradication has fallen below 80% generating renewed interest in novel eradication regimens and targets. In this article, we review the gastric biology of H. pylori and acid acclimation, various detection procedures, antibiotic resistance and the role that gastric acidity plays in the susceptibility of the organism to antibiotics currently in use and propose several novel drug targets that would promote eradication in the absence of antibiotics.
Literatur
1.
Lau JY, Sung J, Hill C, et al. Systematic review of the epidemiology of complicated peptic ulcer disease: incidence, recurrence, risk factors and mortality. Digestion. 2011;84:102–13.PubMedCrossRef
2.
Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet. 1984;1:1311–5.PubMedCrossRef
3.
Genta RM, Graham DY. Comparison of biopsy sites for the histopathologic diagnosis of Helicobacter pylori: a topographic study of H. pylori density and distribution. Gastrointest Endosc. 1994;40:342–5.PubMedCrossRef
4.
Baumgartner HK, Montrose MH. Regulated alkali secretion acts in tandem with unstirred layers to regulate mouse gastric surface pH. Gastroenterology. 2004;126:774–83.PubMedCrossRef
5.
Henriksnas J, Phillipson M, Storm M, et al. Impaired mucus-bicarbonate barrier in Helicobacter pylori-infected mice. Am J Physiol. 2006;291:G396–403.
6.
Scott DR, Marcus EA, Wen Y, et al. Gene expression in vivo shows that Helicobacter pylori colonizes an acidic niche on the gastric surface. Proc Natl Acad Sci USA. 2007;104:7235–40.PubMedCrossRef
7.
Young GM, Amid D, Miller VL. A bifunctional urease enhances survival of pathogenic Yersinia enterocolitica and Morganella morganii at low pH. J Bacteriol. 1996;178:6487–95.PubMed
8.
Castanie-Cornet M-P, Penfound TA, Smith D, et al. Control of acid resistance in Escherichia coli. Volume. 1999;181:3525–35.
9.
Foster JW. Escherichia coli acid resistance: tales of an amateur acidophile. Nat Rev. 2004;2:898–907.CrossRef
10.
Bauerfeind P, Garner R, Dunn BE, et al. Synthesis and activity of Helicobacter pylori urease and catalase at low pH. Gut. 1997;40:25–30.PubMed
11.
Scott DR, Marcus EA, Weeks DL, et al. Mechanisms of acid resistance due to the urease system of Helicobacter pylori. Gastroenterology. 2002;123:187–95.PubMedCrossRef
12.
Weeks DL, Eskandari S, Scott DR, et al. A H+-gated urea channel: the link between Helicobacter pylori urease and gastric colonization. Science. 2000;287:482–5.PubMedCrossRef
13.
Mollenhauer-Rektorschek M, Hanauer G, Sachs G, et al. Expression of UreI is required for intragastric transit and colonization of gerbil gastric mucosa by Helicobacter pylori. Res Microbiol. 2002;153:659–66.PubMedCrossRef
14.
Skouloubris S, Thiberge JM, Labigne A, et al. The Helicobacter pylori UreI protein is not involved in urease activity but is essential for bacterial survival in vivo. Infect Immun. 1998;66:4517–21.PubMed
15.
Voland P, Weeks DL, Marcus EA, et al. Interactions among the seven Helicobacter pylori proteins encoded by the urease gene cluster. Am J Physiol. 2003;284:G96–G106.
16.
Hong W, Sano K, Morimatsu S, et al. Medium pH-dependent redistribution of the urease of Helicobacter pylori. J Med Microbiol. 2003;52:211–6.PubMedCrossRef
17.
• Scott DR, Marcus EA, Wen Y, et al. Cytoplasmic histidine kinase (HP0244)-regulated assembly of urease with UreI, a channel for urea and its metabolites, CO2, NH3, and NH4(+), is necessary for acid survival of Helicobacter pylori. J Bacteriol. 2010;192:94–103. This article shows that in addition to its role as a urea channel, UreI also serves as a membrane anchor for nickel induced activiation of urease and is capable of transporting CO2, NH3 and HH4+ aiding in periplasmic pH homeostasis. PubMedCrossRef
18.
Pflock M, Finsterer N, Joseph B, et al. Characterization of the ArsRS regulon of Helicobacter pylori, involved in acid adaptation. J Bacteriol. 2006;188:3449–62.PubMedCrossRef
19.
Wen Y, Feng J, Scott DR, et al. The pH-responsive regulon of HP0244 (FlgS), the cytoplasmic histidine kinase of Helicobacter pylori. J Bacteriol. 2009;191:449–60.PubMedCrossRef
20.
Meyer-Rosberg K, Scott DR, Rex D, et al. The effect of environmental pH on the proton motive force of Helicobacter pylori. Gastroenterology. 1996;111:886–900.PubMedCrossRef
21.
Lee A, Dixon MF, Danon SJ, et al. Local acid production and Helicobacter pylori: a unifying hypothesis of gastroduodenal disease. Eur J Gastroenterol Hepatol. 1995;7:461–5.PubMed
22.
Clyne M, Labigne A, Drumm B. Helicobacter pylori requires an acidic environment to survive in the presence of urea. Infect Immun. 1995;63:1669–73.PubMed
23.
van Zanten SJ, Kolesnikow T, Leung V, et al. Gastric transitional zones, areas where Helicobacter treatment fails: results of a treatment trial using the Sydney strain mouse model. Antimicrob Agents Chemother. 2003;47:2249–55.PubMedCrossRef
24.
Herrera V, Parsonnet J. Helicobacter pylori and gastric adenocarcinoma. Clin Microbiol Infect. 2009;15:971–6.PubMedCrossRef
25.
Selgrad M, Bornschein J, Rokkas T, et al. Clinical aspects of gastric cancer and Helicobacter pylori–screening, prevention, and treatment. Helicobacter. 2010;15 Suppl 1:40–5.PubMedCrossRef
26.
Takayama S, Wakasugi T, Funahashi H, et al. Strategies for gastric cancer in the modern era. World J Gastrointest Oncol. 2010;2:335–41.PubMedCrossRef
27.
Choi J, Kim CH, Kim D, et al. Aprospective evaluation of a new stool antigen test for detection of Helicobacter pylori, in comparison with histology, rapid urease test, 13C-urea breath test, and rerology. J Gastroenterol Hepatol. 2011.
28.
Leodolter A, Dominguez-Munoz JE, Von Arnim U, et al. Citric acid or orange juice for the 13C-urea breath test: the impact of pH and gastric emptying. Aliment Pharmacol Ther. 1999;13:1057–62.PubMedCrossRef
29.
Pantoflickova D, Scott DR, Sachs G, et al. 13C urea breath test (UBT) in the diagnosis of Helicobacter pylori: why does it work better with acid test meals? Gut. 2003;52:933–7.PubMedCrossRef
30.
Shimoyama T, Sawaya M, Ishiguro A, et al. Applicability of a rapid stool antigen test, using monoclonal antibody to catalase, for the management of Helicobacter pylori infection. J Gastroenterol. 2011;46:487–91.PubMedCrossRef
31.
• Atherton JC, Blaser MJ. Coadaptation of Helicobacter pylori and humans: ancient history, modern implications. J Clin Invest. 2009;119:2475–87. This is an excellent review by the proponents of the controversial view that humans and H. pylori co-evoloved and that H. pylori is a commensal. The authors make a cogent argument that decreased rates of H. pylori infection correlate with a rise in a number of “modern diseases” and therefore H. pylori may be beneficial in preventing these diseases. PubMedCrossRef
32.
Malfertheiner P, Megraud F, O’Morain C, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Volume. 2007;56:772–81.
33.
Blaser MJ. Helicobacter pylori and esophageal disease: wake-up call? Gastroenterology. 2010;139:1819–22.PubMedCrossRef
34.
Chen Y, Blaser MJ. Helicobacter pylori colonization is inversely associated with childhood asthma. J Infect Dis. 2008;198:553–60.PubMedCrossRef
35.
Tan VP, Wong BC. Helicobacter pylori and gastritis: untangling a complex relationship 27 years on. J Gastroenterol Hepatol. 2011;26 Suppl 1:42–5.PubMedCrossRef
36.
Malfertheiner P, Bazzoli F, Delchier JC, et al. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial. Lancet. 2011;377:905–13.PubMedCrossRef
37.
Han F, Liu S, Ho B, et al. Alterations in rdxA and frxA genes and their upstream regions in metronidazole-resistant Helicobacter pylori isolates. Res Microbiol. 2007;158:38–44.PubMedCrossRef
38.
Nakao M, Malfertheiner P. Growth inhibitory and bactericidal activities of lansoprazole compared with those of omeprazole and pantoprazole against Helicobacter pylori. Helicobacter. 1998;3:21–7.PubMedCrossRef
39.
Furuta T, Shirai N, Ohashi K, et al. Therapeutic impact of CYP2C19 pharmacogenetics on proton pump inhibitor-based eradication therapy for Helicobacter pylori. Methods Find Exp Clin Pharmacol. 2003;25:131–43.PubMedCrossRef
40.
Furuta T, Sugimoto M, Shirai N, et al. CYP2C19 pharmacogenomics associated with therapy of Helicobacter pylori infection and gastro-esophageal reflux diseases with a proton pump inhibitor. Pharmacogenomics. 2007;8:1199–210.PubMedCrossRef
41.
• Czinn SJ, Blanchard T. Vaccinating against Helicobacter pylori infection. Nat Rev Gastroenterol Hepatol. 2011;8:133–40. This is an excellent review of the current status of vaccine development for H. pylori infection. The authors present the successes and pitfalls of animal and human vaccines and offer insight for the developement of efficacious vaccines. PubMedCrossRef
42.
Wilhelm SM, Johnson JL, Kale-Pradhan PB. Treating bugs with bugs: the role of probiotics as adjunctive therapy for Helicobacter pylori (July/August). Ann Pharmacother. 2011.
43.
Nishimori I, Minakuchi T, Morimoto K, et al. Carbonic anhydrase inhibitors: DNA cloning and inhibition studies of the alpha-carbonic anhydrase from Helicobacter pylori, a new target for developing sulfonamide and sulfamate gastric drugs. J Med Chem. 2006;49:2117–26.PubMedCrossRef
44.
Scott DR, Marcus EA, Weeks DL, et al. Expression of the Helicobacter pylori ureI gene is required for acidic pH activation of cytoplasmic urease. Infect Immun. 2000;68:470–7.PubMedCrossRef
45.
Wen Y, Marcus EA, Matrubutham U, et al. Acid-adaptive genes of Helicobacter pylori. Infect Immun. 2003;71:5921–39.PubMedCrossRef
Metadaten
Titel
Gastric Infection by Helicobacter pylori
verfasst von
George Sachs
David R. Scott
Yi Wen
Publikationsdatum
01.12.2011
Verlag
Current Science Inc.
Erschienen in
Current Gastroenterology Reports / Ausgabe 6/2011
Print ISSN: 1522-8037
Elektronische ISSN: 1534-312X
DOI
https://doi.org/10.1007/s11894-011-0226-4

Weitere Artikel der Ausgabe 6/2011

Current Gastroenterology Reports 6/2011 Zur Ausgabe

Stomach and Duodenum (Joseph R. Pisegna, Section Editor)

Endoscopic Management of Gastrointestinal Stromal Tumors

Stomach and Duodenum (Joseph R. Pisegna, Section Editor)

Ménétrier’s Disease of the Stomach: A Clinical Challenge

Stomach and Duodenum (Joseph R. Pisegna, Section Editor)

Diagnosis and Management of Pernicious Anemia

Stomach and Duodenum (Joseph R. Pisegna, Section Editor)

Update on the Endoscopic Management of Peptic Ulcer Bleeding

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Frühzeitige HbA1c-Kontrolle macht sich lebenslang bemerkbar

22.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes von Anfang an intensiv BZ-senkend zu behandeln, wirkt sich positiv auf Komplikationen und Mortalität aus – und das offenbar lebenslang, wie eine weitere Nachfolgeuntersuchung der UKPD-Studie nahelegt.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise